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Human telomerase reverse transcriptase is a ribonucleoprotein that synthesises telomeric sequences, which decrease at each cell
division. In cancer cells, its activity is linked to telomere maintenance leading to unlimited cellular proliferation and immortality. To
evaluate the prognostic value of the catalytic subunit telomerase reverse transcriptase (hTERT), we analysed its expression by
immunohistochemistry in 122 formalin-fixed lung tumours including 42 squamous cell carcinoma (SCC), 43 adenocarcinoma (ADC),
19 basaloid carcinoma (BC) and 18 small-cell lung carcinoma (SCLC) in comparison with detection of hTERT mRNA by in situ
hybridisation and relative telomerase activity by TRAP assay in a subset of tumours. We observed a high concordance between
hTERT protein expression and detection of hTERT mRNA and telomerase activity. Telomerase expression varied according to
histology (P¼0.0002) being significantly lower in ADC than in SCC, BC and SCLC (Po0.0001). Adenocarcinoma and SCC exhibited
either a nuclear or a nucleolar staining in contrast with a diffuse nuclear staining observed in most BC and all SCLC (P¼0.01). In stage
I NSCLC telomerase expression was lower than in other stages (P¼0.04), and a nucleolar staining was correlated with a short
survival (P¼0.03). We concluded that telomerase expression and pattern are distinctive among histopathological classes of lung
cancer and convey prognostic influence.
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Lung cancer represents the leading cause of cancer-related death in
industrial countries and comprises about 20% small-cell lung
carcinoma (SCLC) and 80% of non-small-cell lung carcinoma
(NSCLC). According to the new WHO histological classification
(Travis et al, 1999), non-small-cell lung carcinoma include with the
common types squamous cell carcinoma (SCC) and adenocarci-
noma (ADC), a recently described entity, the basaloid carcinoma
(BC), as a variant of large cell carcinoma undergoing a particularly
poor outcome (Brambilla et al, 1992). Surgical resection at early-
stage disease represents the treatment of choice for NSCLC.
However, survival rates remain low fostering identification of new
prognostic factors and therapeutic target such as telomerase with
the aim of deciphering new modes of adjuvant therapies.
Telomeres, which represent the end of the eukaryotic chromo-
somes, shorten at each cell division because of incomplete
replication by DNA polymerase (Henderson, 1995). This results
in telomere shortening leading to chromosome degradation or end
fusion and cellular senescence acting as a ‘mitotic clock’ (Harley
et al, 1990; Hastie et al, 1990; Allsopp et al, 1992). In germ line cells
as well as in tumour cells, telomerase, a ribonucleoprotein complex
composed of a reverse transcriptase catalytic subunit (hTERT) that
copies a template region of RNA subunit (hTERC), can synthesise
telomeric DNA, therefore, allowing cells to proliferate indefinitely
(Counter et al, 1992; Nakamura and Cech, 1998; Holt and Shay
1999). While both hTERC and hTERT are required for telomerase
activity, hTERC is expressed rather ubiquitously, whereas hTERT
is the only limiting factor since its expression is confined to cells
expressing telomerase activity (Meyerson et al, 1997; Nakamura
et al, 1997; Kolquist et al, 1998).
Telomerase activity (TA) evaluated by a sensitive PCR-based
telomere repeat amplification protocol (TRAP) assay has been
widely reported in various malignancies such as liver, colorectal,
brain, prostate and breast cancers as well as leukaemia (Bacchetti
and Counter, 1995; Counter et al, 1995; Langford et al, 1995; Carey
et al, 1998; Tahara et al, 1999; Kawakami et al, 2000). Regarding
malignancies arising in the thorax, several studies have demon-
strated a telomerase activity in SCLC and NSCLC carcinomas
including NE tumours and adenocarcinomas and their precursor
lesion (namely atypical alveolar hyperplasia) as well as in
pulmonary sarcomas and mesotheliomas (Hiyama K et al, 1995;
Ahrendt et al, 1997; Yashima et al, 1997; Gomez-Roman et al, 2000;
Kumaki et al, 2001, 2002; Nakanishi et al, 2002). Almost all SCLC
and the majority of NSCLC display a substantial telomerase
activity in 62–96% of the cases (Hiyama K et al, 1995; Albanell
et al, 1997; Gomez-Roman et al, 2000). Since a close relationship
has been demonstrated between elevated telomerase activity
and a poor prognosis in neuroblastoma and gastric carcinoma
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y(Hiyama E et al, 1995a,b), several reports have also suggested that
high TA or high hTERT mRNA levels should be correlated with a
poor survival in stage I NSCLC (Marchetti et al, 1999, 2002; Wang
et al, 2002). High levels of telomerase have also been associated
with tumour recurrence, histological type, grade (Marchetti et al,
1999, 2002; Kumaki et al, 2001) or smoking status (Xinarianos et al,
1999).
Since several reports have emphasised the use of noncommercial
hTERT antibodies for telomerase analysis in lung cancer,
mesothelioma, colon cancer and liver tissues (Tahara et al, 1999;
Kawakami et al, 2000; Kumaki et al, 2001, 2002), we decided to test
the specificity and the usefulness on a daily practice of a newly
commercially available monoclonal hTERT antibody. In order to
validate this immunohistochemical approach, we compared the
analysis of hTERT protein expression in 122 lung tumours, with
the results of a previously established hTERT in situ hybridisation
technique (Soria et al, 2001) as well as with the standard TRAP
assay performed in a subset of the same tumours. We also
performed a comparative study of other commercially available
hTERT antibodies using immunohistochemistry and Western blot.
This enabled us to assess the value of hTERT immunohistochem-
istry and to show that aggressive lung tumours such as SCLC and
basaloid carcinoma display the highest levels of hTERT expression,
whereas the lowest levels are observed in adenocarcinoma and in
stage I NSCLC.
MATERIAL AND METHODS
Patients and tissue samples
A total of 122 tumour specimens were collected from lung cancer
resections or mediastinal biopsies performed for diagnosis. All
samples were obtained within 1h after surgical removal, and
frozen tumour samples were stored at  801C until protein
extraction for TRAP assay and Western blotting along with
standard formalin or Bouin fixation. Frozen samples were all
analysed histologically and selected for protein extraction with the
requirement of more than 70% of viable tumour cells and less than
10% of stromal lymphocytes. Histopathological and clinical data
including pTNM stages according to the international UICC
classification are listed in Table 1.
Two normal lymph nodes, two normal and two inflammatory
lung tissues with pneumonia were used as positive or negative
controls for immunohistochemistry, in situ hybridisation, Western
blotting and TRAP. Three cancer cell lines, obtained from the
American Type Culture Collection (Manassas, VA, USA), NCI-
H322 (lung ADC), NCI-H69 (SCLC) and HELA (cervical ADC)
were also used as positive controls for Western blotting. The
growing conditions were as follows: RPMI-1640 for NCI-H322,
RPMI-1640 with 100mM 1% sodium pyruvate for NCI-H69 and
DMEM 10% for HELA, all media contained 10% foetal calf serum
under 5% CO2.
Immunohistochemical analysis
In total 3-mm-thick sections were deparaffinised and pretreated for
antigenic heat retrieving 1h at 981C with 10mM citrate buffer pH 6.
In order to compare different hTERT antibodies, a set of 10 normal
and tumour samples were incubated 1–12h at room temperature
with primary polyclonal antibodies raised against hTERT protein
(dilution 10mgml
 1): TRT-L20 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), TEL-1 (Abcam, Cambridge, UK), TERT, Ab-2 and
p123 (Calbiochem, San Diego, CA, USA). All the 122 tumour
samples were also incubated 12h at 421C with a primary
monoclonal hTERT 44F12 antibody (Novocastra, Newcastle upon
Tyne, UK) at the dilution 1:20 (0.35mgml
 1) on paraffin sections.
Immunohistochemical analysis was also performed on frozen
sections with this last antibody at the dilution 1:10 (0.7mgml
 1)a s
control of negative cases. For both techniques, a three-stage
indirect immunoperoxidase technique was performed on Nexes
Ventana automated staining module (Tucson, AZ, USA), which
enables a standardisation of reaction time and temperature,
washing procedures and development of staining and amplifica-
tion. Negative control consisted in omission of the primary
antibody and incubation with immunoglobulins of the same
species. The levels of protein expression were evaluated by two
pathologists (SL and EB). The distribution of staining was graded
as 0: absent, 1: o10%, 2: 10–50%, 3: 51–90% and 4: 490%
and intensity was graded as 1: weak, 2: medium, and 3:
strong. The combined score was performed as follow:
score¼distributionþintensity. Nuclear and/or nucleolar stain-
ings were regarded as specific patterns.
Western blot analysis
In all, 30 tumour samples including 13 SCC, 10 ADC, five BC and
two SCLC, two normal lung specimen and NCI-H322, NCI-H69 and
HELA cancer cell lines were solubilised in Laemmli buffer. Total
proteins were quantified using the Bio-Rad kit (Bio-Rad, Hercules,
CA, USA) and equal amounts of protein were located on a 7.5%
SDS–PAGE gel. Gel was then transferred to nitrocellulose, which
was preincubated with primary telomerase polyclonal antibodies
TRT-L20 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), TEL-1
(Abcam, Cambridge, UK), TERT, Ab-2 or p123 (Calbiochem, San
Diego, CA, USA) or with telomerase monoclonal antibody 44F12,
at the dilution 1:500 at 41C overnight. On the next day, a anti-
mouse biotinylated IgG was used for 1h at room temperature
and immunoreactive bands were visualised using the ECL
Plus
detection system (Amersham, Amersham, UK) as suggested by the
manufacturer. Stained bands when present were qualified as weak
or strong.
In situ hybridisation
For riboprobe generation and RNA in situ hybridisation, a TOPO
TA cloning vector (PCR
sII-TOPO; Invitrogen, Carlsbad, CA, USA)
was used containing a 430bp EcoRV–BamH1 fragment of the
hTERT cDNA as previously described (Soria et al, 2001) to
generate a digoxigenin-labelled RNA probe (riboprobe) specific for
the antisense strand of the hTERT cDNA, which hybridises to the
Table 1 Summary of clinicopathologic features
Variable Number of cases
Mean age; year 61 (range 39–84)
Gender
Male 110
Female 12
Stage (n¼122)
I3 4
II 29
III 55
IV 4
Histological type (n¼122)
SCC 42
ADC 43
BC 19
SCLC 18
Metastases
Visceral 20/84 (24%)
Lymph node 61/122(50%)
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enzyme.
In situ hybridisation was performed on paraffin-embedded
tissue sections from 20 tumour samples including five ADC, seven
BC, seven SCC and one SCLC, in RNAse-free conditions. The slides
were transferred on the heating blocks of a Discovery module
(Ventana Medical System, Strasbourg, France) for an automatised
in situ hybridisation procedure. Briefly, the sections were treated
with 2.5mgml
 1 proteinase K (Roche Diagnostics, Meylan, France)
for 14min at 371C and postfixed in 4% paraformaldehyde for 8min
at room temperature. The antisense riboprobe diluted at
800ngml
 1 in hybridisation buffer was denatured and 100ml
applied on each sections for an incubation of 8h at 421C. Sense
and antisense actin riboprobes have been used as negative and
positive controls, respectively, to assess the good mRNA preserva-
tion in the same conditions on duplicate slides. Slides were then
incubated overnight at room temperature with an alkaline
phosphatase-conjugated antidigoxigenin antibody (dilution
1:200, Roche Diagnostics, Meylan, France). Alkaline phosphatase
was detected using 5-bromo-4-chloro-3-indolyl phosphate and
nitro-blue tetrazolium chloride (Roche Diagnostics, Meylan,
France) as chromogens. The levels of hTERT mRNA expression
were evaluated by two pathologists (SL and EB). The same score
system than for immunohistochemistry data combining distribu-
tion and intensity of staining was applied. Cytoplasmic pattern was
considered as a specific positive staining.
TRAP assay
The kit Telo TAGGG telomerase PCR ELISA
plus (Roche Molecular
Biochemicals, Mannheim, Germany), a photometric enzyme
immunoassay, was used for quantitative determination of telo-
merase activity. Frozen sections from 40 tumour samples, two
normal lymph nodes, two normal lungs and one with pneumonia
were analysed histologically to assess the amount of tumour
component (at least 70% of tumour cells), and the quality of
material (i.e. absence of necrosis). All steps of the assay protocol
were performed in RNAse-free conditions. In total, 20 10-mm-thick
frozen sections of each specimen were cut, immediately lysed in
200ml of ice-cold CHAPS (3-{[3-chlomidopropyl]-dimethyl-am-
monio}-1-propanesulphonate) lysis buffer, homogenised, incu-
bated on ice for 30min and centrifuged at 12000g for 20min at
41C. In all, 2ml of each sample, with heat-inactivated controls, were
mixed with 48ml of reaction mixture containing telomerase
substrate, biotin labelled P1-TS and P2 primers, nucleotides and
Taq polymerase in Tris buffer. Reverse transcription was
performed for 30min at 251C and PCR amplification consisted
in a three-step PCR at 941C3 0 s ,5 0 1C 30s and 721C 90s for 30
cycles followed by a 721C 10-min extension step. Evaluation of the
relative telomerase activity (RTA) was determined by the
measurement of the absorbance of each sample at a wavelength
of 450nm (reference wavelength, 595nm, Microplate Reader 3550,
Bio Rad). Cases were considered as positive when RTA was higher
than 0.2.
Statistical analysis
The staining scores were compared in different categories
using the Mann–Whitney U test and Kruskal–Wallis H
tests. The w
2 test was used to test the association between two
categorical variables. Survival times were calculated from the date
of surgery from cancer-related events. Survival curves were
estimated by the method of Kaplan–Meier. The log-rank
test was used to compared survival curves. P-values less than
0.05 were considered as statistically significant. All the tests were
performed with the Stat View program (Abacus Concepts,
Berkeley, CA, USA)
RESULTS
Immunohistochemical analysis of human TERT
Using TRT-L20 and TEL-1 polyclonal antibodies, a nuclear
staining was observed in tumour cells and activated lymphocytes
but also in stromal and epithelial normal cells. With TERT and Ab-
2 polyclonal antibodies, nuclear staining was observed in tumour
cells whereas activated lymphocytes and normal cells remained
negative. All cells exhibited a strong cytoplasmic staining. In
contrast, no nuclear staining could be demonstrated with p123
polyclonal antibody regardless of cell type.
Using monoclonal antibody 44F12, a mild to moderate nuclear
immunostaining with nucleolar reinforcement (intensity 1 or 2)
was observed on about 50% of basal cells of normal bronchial
epithelium (Figure 1A, left). Serous cells of bronchial glands also
displayed a frequent focal nucleoplasmic and nucleolar-positive
staining, whereas alveolar pneumonocytes and endothelial cells
remained negative (Figure 1A, right). In contrast, 50–80% of
lymphocytes present in the bronchial mucosae or infiltrating
alveolar walls in inflammatory lungs (Figure 1A) showed a
moderate nuclear staining and served as internal positive control
with a staining intensity of 2 for grading the intensity of staining in
neoplastic cells (from 1 to 3).
Among 122 cases of lung tumours, 116 were hTERT positive
(95%) with 44F12 monoclonal antibody. This included all
cases of SCLC, BC and SCC and 86% of adenocarcarcinomas (37
out of 43) (Figure 1C, E, G, J). All results concerning scores and
staining pattern of hTERT expression in lung tumours are
summarised in Table 2. Positive staining in tumour cells was
located on nucleus, either restricted to nucleolar structures
(Figure 1B), or diffuse in the nucleoplasm with nucleolar
reinforcement. The first pattern, exclusively nucleolar, was more
frequently observed in SCC (14 out of 42; 33%) and in ADC (16 out
of 43; 37%) than in BC (5 out of 19; 26%), and SCLC (none)
(P¼0.01) (w
2 test). We did not observe a nucleolar exclusion in
cases with diffuse nuclear pattern.
Tumoral heterogeneity in hTERT expression distribution was
frequent, whatever the histological type of tumour considered.
Furthermore, ADC exhibited either low or moderate levels of
hTERT expression in contrast with BC, SCLC and SCC presenting
Figure 1 Expression in nontumoral lung and in lung tumours of hTERT as compared with hTERT mRNA by immunohistochemistry and in situ
hybridisation. (A) (left): Mild to moderate hTERT immunostaining (intensity 1) of basal cells of normal bronchial epithelium with nucleolar reinforcement
(arrow) and moderate staining (intensity 2) of activated lymphocytes in bronchial mucosae (immunoperoxidase staining,  200). (A) (right): hTERT positive
staining in a lymphocytic aggregate (arrow) in an inflammatory lung. Alveolar epithelial cells are negative (immunoperoxidase staining,  100). (B) A typical
nucleolar staining (arrow) in an ADC (immunoperoxidase staining,  400). (C) hTERT immunostaining in SCC exhibiting a strong nucleolar staining
(intensity 3) (arrow) (immunoperoxidase staining,  100). (D) mRNA expression observed by in situ hybridisation in the cytoplasm of tumoral cells and
stromal lymphocytes in the same case as 1C ( 100). (E) hTERT immunostaining in ADC exhibiting a strong nuclear staining (intensity 3)
(immunoperoxidase staining,  100). (F) mRNA expression in the same case as 1E shown by in situ hybridisation ( 100). (G) hTERT immunostaining in
BC showing a strong and diffuse nuclear staining (intensity 3) (immunoperoxidase staining,  100). (H) mRNA expression shown by in situ hybridisation in
the cytoplasm of tumour cells and stromal lymphocytes (arrow) in the same case of BC ( 100). (J) Strong and diffuse nuclear hTERT immunostaining
(intensity 3) in a SCLC (immunoperoxidase staining,  200). (K) mRNA expression shown by in situ hybridisation in the same case as J ( 200).
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mixed type ADC with predominant BAC peripheral pattern
(lepidic growth), only three exhibited telomerase expression in
the lepidic growth. The distribution of the levels of telomerase
expression among histological type were statistically different
(P¼0.0002) (Kuskal–Wallis H test), and hTERT scores were
significantly lower in ADC than in SCC, BC and SCLC taken
together (Po0.0001) (w
2 test).
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With polyclonal antibody p123, numerous nonspecific bands were
seen on lysates from cell lines, normal or tumour samples. In
contrast, with TRT-L20, TEL-1, TERT and Ab-2 antibodies, no
specific stained band was observed using several cell line lysates or
from tumour samples.
Using 44F12 antibody, all cancer cell lines strongly exhibited a
positive and unique band of approximately 105kDa consistent
with the theoretical estimation of telomerase molecular weight of
127kDa (Wick et al, 1999). This band was totally absent in two
normal lung samples. Among lung cancers, 24 out of 30 cases
(80%) displayed an hTERT expression with a unique band of
105kDa, 17 cases exhibiting a strong staining and seven a weak
expression (Figure 2). One SCLC and one BC exhibited a double
band both located around 105kDa (data not showed), but this
phenomenon was too rare to enable us any conclusion about a
possible phosphorylation.
In situ Hybridisation with hTERT riboprobe
In situ hybridisation staining with hTERT riboprobe was located in
the cytoplasm and had the same cell distribution than that obtained
by immunohistochemistry. It was negative in most normal lung
structures but positive in a few basal bronchial cells, serous cells of
bronchial glands and lymphocytes. Hybridisation with sense actin
riboprobe gave an expected negative signal in all cell type.
All 20 lung tumours were strongly positive, with no staining on
stromal cells except activated lymphocytes (Figure 1 D, F, H, K).
The scores of expression ranged from 4 to 6; nevertheless, the
small number of cases precluded demonstration of a statistical
significance according to histological types.
TRAP assay
In two normal lungs, two with pneumonia and two normal lymph
nodes, RTA remained negative. In all, 34 out of 40 cases of lung
tumours (85%) of all histological types exhibited levels of RTA
higher than 0.2, including 64% of ADC, 64% of SCC, 92% of the
BC, and the SCLC case. The RTA levels were significantly higher in
BC (1.2870.69 RTA) than in SCC (0.6870.84 RTA) and in ADC
(1.0970.58) (P¼0.03 BC vs SCC and ADC considered together).
The only SCLC case studied exhibited a very high RTA (1.789
RTA).
Concordance between data obtained by Western blotting
and by immunohistochemistry (Table 3)
Weak or negative stained bands correlated with immunohisto-
chemical scores lower than score 4 in eight cases. Conversely, a
strong Western blot staining was observed in 16 cases presenting
immunohistochemical scores of 4–7. One case presented a strong
WB staining despite a negative immunohistochemical staining
(ADC6), and six cases exhibited a negative or weak WB staining
despite high scores of HTERT expression by immunohistochem-
istry (SCC6, SCC7, SCC10, ADC2, BC5 and SCLC1). Overall, a
concordance between data obtained by immunohistochemistry
and Western blotting was of 76%.
Table 2 Differential immunohistochemical hTERT expression in lung tumours (scores and pattern of staining)
Histology (nb of cases)
(n¼122)
Distribution of scores: nb of cases (%) Staining pattern distribution: nb of cases
0 2 and 3 4 and 5 6 and 7 Nuclear Nucleolar
ADC (43) 6 (14%) 17 (40%)1 8 ( 42%) 2 (4%) 16 12
SCC (42) 7 (16.6%) 28 (66.6%) 7 (16.6%) 17 14
BC (19) 2 (10%) 13 (68%)4 ( 21%) 14 5
SCLC (18) 1 (5%) 13 (72%)4 ( 22%) 18
Figure 2 Western Blotting showing a 105kDa hTERT product with
hTERT 44F12 antibody in cancer cell line H69, normal lung (NL) and a
subset of lung carcinoma including SCC and ADC
Table 3 Comparison of Western blotting staining intensity and
immunohistochemical scores of hTERT expression in a subset of 30 lung
tumours including 13 SCC, 10 ADC, five BC and two SCLC
Histology Western blotting Immunohistohemical scores
SCC 1 Strong 6
SCC 2 Negative 3
SCC 3 Strong 5
SCC 4 Strong 4
SCC 5 Strong 6
SCC 6 Weak 4
SCC 7 Negative 4
SCC 8 Weak 3
SCC 9 Strong 4
SCC 10 Weak 4
SCC 11 Strong 5
SCC 12 Strong 5
SCC 13 Strong 5
ADC 1 Weak 3
ADC 2 Weak 4
ADC 3 Weak 3
ADC 4 Strong 4
ADC 5 Strong 5
ADC 6 Strong 0
ADC 7 Negative 3
ADC 8 Strong 5
ADC 9 Weak 3
ADC 10 Strong 5
BC 1 Strong 7
BC 2 Strong 5
BC 3 Negative 3
BC 4 Negative 3
BC 5 Weak 6
SCLC 1 Weak 4
SCLC 2 Strong 5
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immunohistochemistry, in situ hybridisation, and TRAP
Among 40 cases analysed concomitantly by TRAP and immuno-
histochemistry, 34 (85%) were positive with both techniques. In
the six TRAP negative tumours, no RTA was detected despite
hTERT protein expression in five cases and one case had neither
RTA nor protein expression. In all, 24 tumours exhibited either
low levels of RTA (p0.5) and low hTERT scores 2 or 3, or high
levels of RTA (more than 0.5) and high hTERT combined scores of
4–7 in concordance. Conversely, 10 cases were discordant: four
cases showed low RTA but high hTERT staining scores of 5 or 6,
and six cases high RTA but low hTERT staining score 3. Overall, a
concordance of 70% between the levels of activity and scores of
hTERT immunohistochemical expression was observed.
Among these 40 cases, 18 were concomitantly studied by in situ
hybridisation and immunohistochemistry, showing that protein
expression was always observed when hTERT mRNA and
telomerase activity were measurable. Among 20 cases studied by
both in situ hybridisation and immunohistochemistry, six cases
exhibited high levels of hTERT mRNA (scores 5 or 6) and a low
protein staining score of 3. Concordance between immunohisto-
chemical analysis and in situ hybridisation was of 70%. Nucleolar
staining was also observed when telomerase activity was detected
(in 10 tumours), or mRNA were present (five cases) or both (five
cases), as well as when a specific band was observed in Western
blot (five cases).
Correlation between telomerase expression and
clinicopathologic features
Immunohistochemical or in situ hybridisation staining scores or
RTA values were not correlated with gender or patient age.
Telomerase expression determined by TRAP or immunohisto-
chemistry was lower in stage I lung carcinomas (including 24 ADC,
six SCC and four BC) than in other stages (II–IV) (P¼0.03 for
TRAP values and P¼0.04 for hTERT scores) (Mann–Whitney U
tests). However, no statistical evidence of an influence of levels of
hTERT expression on survival was observed when all histological
types were considered together or when SCLC and BC or SCC and
ADC were considered separately. No correlation was observed
between staining pattern and scores of protein expression,
whatever the histological type and the disease stage considered.
In contrast, a nucleolar pattern of hTERT staining, which was
observed in four BC and 11 ADC out of 34 stage I NSCLC,
correlated with a shorter survival (P¼0.03) (Figure 3).
DISCUSSION
We have demonstrated here that telomerase expression varies
significantly according to the histological type of lung tumours.
Adenocarcinoma displayed the lowest level of telomerase activity
especially at stage I and in the lepidic growth of mixed type ADC.
This is in agreement with previous reports where telomerase
activity in ADC ranged from 40 to 88% of positive cases, the lowest
levels of expression being observed in bronchioloalveolar carci-
noma (Hiyama K et al, 1995; Marchetti et al, 1999; Fujiwara et al,
2000) and in well-differentiated ADC of Clara cell type (Fujiwara
et al, 2000). Indeed, we found a clear difference in the telomerase
expression between the invasive compartment and the peripheral
noninvasive lepidic growth of the mixed ADC with BAC
predominant pattern.
In contrast, BC, which are truly aggressive lung tumours, exhibit
similar high levels of telomerase expression than the SCLC,
another well-known fast-growing tumour with 6 month mean
survival. Basaloid carcinoma are rare tumours with a mean
survival at stage I and II of 606 days as compared with 1218
days for SCC with which they had been confused (Brambilla,
1997). Telomerase activity in BC has never been reported yet
since they represent a recent entity firstly described in 1992
(Brambilla et al, 1992) and now recognised in the new WHO
histological classification of lung tumours in 1999 (Travis et al,
1999).
We observed a lower expression of hTERT in stage I NSCLC but
no influence of telomerase levels of expression on survival rate.
This point remains controversial (Hara et al, 2001; Toomey et al,
2001) although several authors strongly support the unfavourable
prognostic value of a high telomerase expression in stage I NSCLC
(Marchetti et al, 1999, 2002; Wang et al, 2002). Controversies
regarding telomerase levels in tumours reside in the variety of
technical approaches. Most previous data are based on telomerase
activity measured by TRAP assay or quantification of
hTERT mRNA by RT–PCR requiring samples containing at least
5000 viable tumour cells and obtained freshly in RNAse-free
conditions. Sample contamination by telomerase negative normal
epithelial or stromal cells might explain TRAP negative assay,
whereas positive activated lymphocytes might contribute to a
positive TRAP assay in the absence of telomerase activity in
tumour cells (Cunningham et al, 1998; Xinarianos et al, 2000). A
requirement of 70–80% of cancer cells seems reasonable in order
to compare telomerase levels to external standards provided by cell
lines (Marchetti et al, 2002). Furthermore, the exactitude of any
measurement of telomerase activity is challenged by intratumoral
heterogeneity of hTERT expression (Kumaki et al, 2001; Paradis
et al, 2001). We and others have experienced successful hTERT in
situ hybridisation approaches, which evaluate the level of
transcription of hTERT (Kolquist et al, 1998; Soria et al, 2001;
Wang et al, 2002). However, this technique remains time and
labour-consuming. Therefore, the most promising tool for an in
situ evaluation of telomerase expression is now represented by
immunohistochemical detection of hTERT. To date, studies using
noncommercially available antibodies have shown the nuclear
expression of hTERT in tumour cells of various type, as well as in
progenitor cells and activated lymphocytes and no expression in
normal somatic cells. Among different commercially available
antibodies against hTERT, only the monoclonal 44F12 antibody
gave us both a unique and specific band on Western blotting
and a clear-cut nuclear staining only in tumour component and
activated lymphocytes. Furthermore, we found a high concordance
between semiquantitative approaches of hTERT expression
evaluated by immunohistochemistry and Western blotting on a
same sample set.
A good correlation has been demonstrated between TRAP and
hTERT immunohistochemical detection (Tahara et al, 1999;
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Figure 3 Survival curve of stage I NSCLC patients according to
subcellular location of hTERT immunohistochemical staining (P¼0.03).
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tumours, liver tissues, lung cancer and mesothelioma. Our
immunohistochemical approach in the setting of lung cancer
was confronted to the TRAP assay as well as to hTERT
in situ hybridisation and standard Western blotting.
Similar profiles of RTA levels and hTERT staining scores
were observed in lung tumours, higher levels being noted
in SCLC and BC than in SCC and ADC. However in five cases
where protein was detected by immunohistochemistry, telomerase
activity was absent, and in 10 other cases, levels of telomerase
expression evaluated by TRAP assay and immunohistochemistry
were discordant. Such discrepancies might be explained by
dilution of tumoral positive cells in the sample or by post-
transcriptional and post-translational regulations of the protein
quantitatively and qualitatively. As an example, the level of
phosphorylation is able to control both telomerase activity (Li
et al, 1997; Kang et al, 1999) and cytoplasmic vs nuclear
localisation of hTERT (Kharbanda et al, 2000; Liu et al, 2001;
Kyo and Inoue, 2002).
Interestingly, we reported for the first time a nucleolar
localization of the catalytic subunit hTERT, preferentially
located onto nucleolar structures in 45% of SCC and 42% of
ADCs in contrast with its diffuse nuclear localization in all SCLC
and 74% of BC. We have considered this pattern of staining as
specific as it was observed in a number of TRAP and Western blot
positive tumours. Indeed, compelling evidence has been provided
that the assembly of hTERT subunit and hTERC RNA via box H/
ACA motif takes place into the nucleolus favouring the hTERC
maturation and the stabilization of the telomerase protein
complex (Mitchell et al, 1999). Nucleolar localisation of hTERT
seems also to occur independently of hTERC binding, suggesting
that this phenomenon could correspond to a sequestration of
hTERT away from its telomeric targets (Etheridge et al, 2002). In
addition, subnuclear distribution of hTERT may vary according to
cell cycle stage or DNA damage. Thus in normal cells, telomerase is
released to the nucleoplasm during the S phase where it can add
telomeric sequences to replicating chromosomes. In contrast, in
response to ionising radiation, telomerase is excluded from the
nucleoplasm and accumulated into the nucleolus in order to
limit its accessibility to nontelomeric ends and to prevent its
association to inappropriate substrates during the repair of
DNA breaks (Wong et al, 2002). Conversely in SV 40 transfected
cells, oncogenic transformation triggers the releasing of
hTERT into the nucleoplasmic compartment increasing the
telomeric sequence synthesis (Wong et al, 2002). Since we report
here a shorter survival in stage I NSCLC exhibiting a nucleolar
pattern of staining, several hypotheses concerning the signification
and the prognostic implication of nucleolar hTERT confinement
may be proposed. The nucleolar localisation in some ADC and
SCC is consistent with a regulated compartmentalised type of
hTERT accumulation process where telomere elongation remains
separated from DNA repair process during the S phase, thus
protecting DNA from genetic instability and inopportune crisis
(Wang et al, 2002). In contrast, concomitant nucleolar and nuclear
distribution observed in aggressive tumours such as SCLC and BC
is suggestive of a strong and aberrant increase of telomerase
activation in fast-growing tumours that have acquired a large
enough number of genetic lesions to escape senescence and
apoptosis.
As telomerase inhibitors may be mainly effective after multiple
cell divisions leading to cell death, they may have their greatest
impact in combination with cytotoxic chemotherapy in advanced-
stage disease and in high-grade tumours, such as BC and SCLC as
well as in adjuvant therapy to surgery in early-stage disease.
Although nucleolar localization in early NSCLC deserves specific
attention, further studies need to be performed to improve our
knowledge about telomerase regulation through its subnuclear
distribution and cell cycle dependency in order to clarify the
fundamental basis of the prognostic influence of hTERT nucleolar
localisation.
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